. Author manuscript; available in PMC: 2011 Mar 2.

Published in final edited form as: J Urol. 2010 Oct 16;184(6):2313–2319. doi: 10.1016/j.juro.2010.08.012

Table 2.

Summary of QTcF results in subjects with QRS 120 msec or less at baseline

	Degarelix 240/80 mg	Degarelix 240/160 mg	Pooled Degarelix	Leuprolide 7.5 mg
Baseline:
No.	191	183	374	184
Mean (SD)	405 (19.8)	401 (18.5)	403 (19.2)	403 (18.8)
Day 3:
No.	188	181	369	181
Mean (SD)	409 (22.8)	402 (18.4)	405 (21.0)	403 (21.8)
Change (SD)	4.43 (15.4)	0.576 (16.6)	2.54 (16.1)	0.198 (17.5)
Mean % change	1.06	0.148	0.612	0.0132
End of trial:
No.	191	185	376	184
Mean (SD)	419 (21.9)	413 (20.6)	416 (21.4)	417 (22.3)
Change (SD)	14.1 (18.4)	11.9 (15.9)	13.0 (17.2)	14.0 (20.4)
Mean % change	3.46	2.94	3.21	3.45

Patients with baseline QRS greater than 120 msec were excluded from the QTc analysis.